Charles Ray Jones has found that according to his clinical experience, only 7% of the pediatric patients report having an EM rash, while secondary EM rashes are reported in 3% to 5% of his patients. (The CDC reports the rash is present in 70% – 80% of cases.) Dr. Studies have found the EM rash is absent in more than 50% of Lyme disease cases. The study was funded by the Bay Area Lyme Foundation and Laurel STEM Fund.The number of patients who have an EM rash has been disputed. Potula, PhD, senior research scientist postdoctoral scholars Aditya Ambati, PhD, and Venkata Mallajosyula, PhD senior research scientist Mohammed Inayathullah, PhD and intern Mohamed Sohail Ahmed.Ī researcher at Loyola College in India also contributed to the work. Other Stanford co-authors are Hari-Hara S. Rajadas is also a professor of bioengineering and therapeutic sciences at the University of California-San Francisco. Researchers plan to conduct a clinical trial. Pothineni and Rajadas have patented the compound for the treatment of Lyme disease and are working with a company to develop an oral form of the drug. burgdorferi in lab dishes, indicating that it may work as a therapy for lingering symptoms of Lyme disease. For the first time, azlocillin was also shown to be effective in killing drug-tolerant forms of B. The drug, which is not on the market, was tested in mouse models of Lyme disease at seven-day, 14-day and 21-day intervals and found to eliminate the infection. Whatever the cause, the pain for patients is still very real.” Azlocillin comes out on top “Some researchers think this may be due to drug-tolerant bacteria living in the body and continuing to cause disease,” said Rajadas, who is also a member of the Lyme Disease Working Group at Stanford. “Others believe it’s an immune disorder caused by bacteria during the first exposure, which causes a perpetual inflammation condition. Traditional antibiotics, such as doxycycline, are effective as an early course of treatment for the infection in the majority of patients, but it remains unclear why these drugs fail to treat 10% to 20% of patients, Rajadas said. Symptoms include fever, headaches, chills, and muscle and joint pain. It can affect various organs, including the brain, skin, heart, joints and nervous system, and cause heart problems and arthritis if untreated. burgdorferi and causes fewer side effects. Lyme disease affects more than 300,000 people annually, according to the Centers for Disease Control and Prevention. In this most recent study, azlocillin, one of the top-20 contenders, was shown to eclipse a total of 7,450 compounds because it is more effective in killing B. One, for instance, is used to treat alcohol abuse disorder. All 20 had been approved by the Food and Drug Administration for various uses. Our main goal is to find the best compound for treating patients and stop this disease.” Hunting for alternative drugįrustrated by the lack of treatment options for Lyme disease patients with lingering symptoms, Rajadas and his team began hunting for a better alternative in 2011. In 2016, they published a study in Drug Design, Development and Therapy that listed 20 chemical compounds, from about 4,000, that were most effective at killing the infection in mice. Along the way, I’ve met many people suffering with this horrible, lingering disease. The most effective and safest molecules were tested in animal models. “We’ve screened almost 8,000 chemical compounds. “We have been screening potential drugs for six years,” Pothineni said. The lead author is research associate Venkata Raveendra Pothineni, PhD. We are hoping to repurpose it as an oral treatment for Lyme disease.” Rajadas is the senior author of the study, which was published online March 2 in Scientific Reports. “It clears the infection without a lot of side effects. “This compound is just amazing,” said Jayakumar Rajadas, PhD, assistant professor of medicine and director of the Biomaterials and Advanced Drug Delivery Laboratory at the Stanford School of Medicine. The study suggests it could also be effective for treating patients infected with drug-tolerant bacteria that may cause lingering symptoms. But for up to 20% of people with the tick-borne illness, the antibiotics don’t work, and lingering symptoms of muscle pain, fatigue and cognitive impairment can continue for years - sometimes indefinitely.Ī new Stanford Medicine study in lab dishes and mice provides evidence that the drug azlocillin completely kills off the disease-causing bacteria Borrelia burgdorferi at the onset of the illness. For decades, the routine treatment for Lyme disease has been standard antibiotics, which usually kill off the infection.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |